Taken together, these results reveal that modulation of UBQLN2 expression could hold great promise as part of a novel therapeutic strategy to improve the efficacy of radiotherapy for ESCC patients. This evidence concerns the gene UBQLN2 and esophageal squamous cell carcinoma.